Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 25, 2006 Stephen D. Simpson	Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note.
The Motley Fool July 23, 2008 Brian Orelli	Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down.
BusinessWeek June 7, 2004 Gene G. Marcial	St. Jude's Bruise Should Clear Up Fast St. Jude Medical (STJ ) tumbled 2%, to $73, after it revealed that the FDA had delayed for a month the approval of its new Epic CRT-defibrillator.
The Motley Fool July 19, 2006 Stephen D. Simpson	Taking St. Jude's Pulse The ICD market is a long-term opportunity, but not a panacea. St. Jude investors should remember that this is a rough neighborhood -- product liability, FDA bureaucracy, and huge, tough competitors live here, too.
The Motley Fool October 19, 2007 Billy Fisher	Keeping Pace at St. Jude Medical device maker St. Jude Medical has a strong quarter, but investors weren't impressed.
The Motley Fool July 21, 2010 Brian Orelli	Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now.
The Motley Fool March 16, 2010 Brian Orelli	No Matter What You Call It, It Still Stinks A recall over a paperwork issue? What have you guys been doing? Announcing a recall of your heart defibrillators during a major cardiology meeting probably isn't the best move
The Motley Fool June 24, 2009 Brian Orelli	Boston Scientific Helps Itself ... and Its Rivals Boston Scientific released positive results from a clinical trial testing its heart devices, but unfortunately the data is likely to help its competitors as well.
The Motley Fool December 5, 2005 Stephen D. Simpson	Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note.
The Motley Fool February 12, 2010 Brian Orelli	Too Bad It's Not in the "Restructuring" Business Shares of Boston Scientific slipped nearly 10% yesterday, after the company released earnings and guidance for this year.
The Motley Fool January 9, 2007 Billy Fisher	St. Jude's Juiced-Up Q4 The medical-device maker shows stronger vital signs. Investors, take note.
The Motley Fool July 18, 2008 Brian Orelli	St. Jude Is a Fighter The medical device maker continues to kick the competition while it's down.
The Motley Fool April 11, 2008 Brian Orelli	St. Jude's Heartfelt Acquisition Medical-device maker St. Jude purchases tiny EP MedSystems.
The Motley Fool April 9, 2010 Brian Orelli	Is Boston Scientific Turning It Around? Selling off a pair of units could help.
The Motley Fool October 20, 2009 Robert Steyer	The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it.
The Motley Fool July 29, 2011 Brian Orelli	Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last?
The Motley Fool April 18, 2006 Stephen D. Simpson	Get Ready for the New Boston Scientific Here's hoping it does a better job as a bigger business. For all of the risks that are present, there still could be rewards here for investors.
The Motley Fool February 5, 2008 Brian Orelli	Boston Scientific Gets Charged Walloped by charges, Boston Scientific posts a loss for the quarter.
The Motley Fool May 25, 2010 Brian Orelli	Medtronic Gets Tossed Out With the Bathwater A bad day to report good news.
The Motley Fool February 3, 2011 Thomas Lee	Boston Scientific Wants to Be a Rock Star. But First, It Needs Some Stars Boston Scientific has been talking the talk of late. But its walk the past few years can be best described as a limp.
The Motley Fool April 19, 2007 Billy Fisher	A Saintly Quarter Shares of St. Jude Medical rise after the company announces a big quarter.
The Motley Fool October 30, 2009 Selena Maranjian	Big Gains and Minimal Taxes Many fund investors will enjoy a silver lining come tax time.
The Motley Fool September 14, 2011 Brian Orelli	How to Muck Up a Turnaround in 12 and a Half Months Boston Scientific's choice for a new CEO has the potential to really muck up its recovery even further -- if that's even possible.
The Motley Fool November 21, 2006 Ryan Fuhrmann	Shocking Results at Medtronic Favorable earnings boost shares of this medical equipment maker -- but are they too high already?
The Motley Fool February 1, 2010 Brian Orelli	Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost.
The Motley Fool April 25, 2011 Arundhati Parmar	St. Jude: New Aortic Replacement Valve Approved St. Jude gets good news.
The Motley Fool September 21, 2010 Brian Orelli	An Acquisition Helps Boston Scientific Breathe Easier Boston Scientific diversifies by picking up device maker Asthmatx.
The Motley Fool June 26, 2009 Brian Orelli	Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss.
The Motley Fool April 19, 2006 Stephen D. Simpson	St. Jude Lives and Learns Though dynamics in the ICD market caught it by surprise, this is still a quality med-tech company. Investors, take note.
The Motley Fool April 21, 2009 Brian Orelli	Boston Scientific Rebuilds Whether the company is a value or a value trap depends on how well the rebuilding goes this year.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Stimulating Merger St. Jude will be paying $61.25 a share in cash for Advanced Neuromodulation Systems, a robust 30% premium to Friday's closing price. This deal demonstrates that large med-tech players may still be on the prowl for avenues into fast-growing new markets.
The Motley Fool July 25, 2011 Jordan DiPietro	Should You Retire With St. Jude? I can't decide for you whether or not this is the best stock for retirement, but it has passed all four tests, which is pretty impressive.
InternetNews February 26, 2009 Paul Shread	IBM's Good News No Help For Stocks IBM may be doing well, but the same can't be said for the rest of the stock market.
The Motley Fool January 20, 2012 Eric Bleeker	Why Tech Stocks Should Drive the Dow Higher Today A series of tech earnings could put the Dow in positive territory.
The Motley Fool July 20, 2006 Rick Aristotle Munarriz	The Black Hole of Investing Savor the opportunity to pick up quality, growing companies at significant discounts. While stock prices may head even lower, nailing the bottom is nearly impossible.
The Motley Fool January 18, 2012 Dan Caplinger	Has St. Jude Medical Become the Perfect Stock? St. Jude took a big step toward perfection when it initiated a big dividend in early 2011.
The Motley Fool January 19, 2006 Stephen D. Simpson	Big, Blue, and Known All Over Though it's a reasonable default proxy for technology, diligent investors can probably do better than IBM.
The Motley Fool April 27, 2010 Brian Orelli	Boston Scientific's "Challenging" Quarter Boston Scientific fixed its paperwork problem with the Food and Drug Administration earlier this month, but the resulting recall took its toll on first-quarter profits nonetheless.
The Motley Fool April 5, 2006 Stephen D. Simpson	St. Jude's Racing Heartbeat Slows Even though the stock got far too expensive, this is still a good company and could still be a viable target for certain large health-care companies that may be in an acquisition frame of mind.
BusinessWeek March 22, 2004 Robert Barker	St. Jude: An Insider Sign To Investors? St. Jude, the patron saint of lost causes, rarely has needed to look out for his namesake, St. Jude Medical (STJ ). Since its birth in 1976, this maker of artificial heart valves, defibrillators, catheters, and sundry other cardiac devices has led a blessed life. It's in excellent health today. So why are insiders dumping the stock?
U.S. CPSC April 3, 2003	Change Smoke Alarm Batteries When Changing Clocks for Daylight Saving Time The U.S. Consumer Product Safety Commission (CPSC) urges consumers to change their smoke alarm batteries when changing their clock for Daylight Saving Time this Sunday, April 6.
The Motley Fool October 11, 2010 Anders Bylund	Suntech Power Shares Popped: What You Need to Know Shares of Suntech Power Holdings are up significantly today, gaining more than 11% from Friday's close.
The Motley Fool January 11, 2008 Brian Orelli	Boston Scientific Lives Below Its Means Cost-cutting efforts should help turn the medical-device making company around in 2008.
The Motley Fool September 28, 2004	How to Think About Diversification There's no absolute best number of stocks to own. Too few and you've taken on too much risk. Too many and you've diluted the power of your holdings more than you had to.
The Motley Fool February 8, 2006 Tim Beyers	Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's buying now? Dominion Resources... Goodrich Petroleum... iPass... ITT Educational Services... St. Jude Medical...
The Motley Fool February 3, 2011 Brian Orelli	Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes.
The Motley Fool June 29, 2004 Rich Smith	Thomson's Patently Good Buy Thomson will purchase Information Holdings, a provider of intellectual property information. The acquisition would significantly boost Thomson's scientific and health-care business.
The Motley Fool October 12, 2004 Jeff Hwang	The Phantom Stock Split "Boost" If St. Jude Medical's stock went up, it's not because it's worth any more.
The Motley Fool September 29, 2010 Brian Orelli	Boston Scientific: Strengths, Weaknesses, Opportunities, Threats One of the best ways to develop a picture of any company is with the SWOT analysis -- a look at a company's strengths, weaknesses, opportunities, and threats. Let's take a look at Boston Scientific in this light as it tries to turn itself around.
The Motley Fool June 27, 2007 Selena Maranjian	Meet Some Weird Mutual Funds Here is a look at some odd mutual funds.